+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families



A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families



American Journal of Human Genetics 60(5): 1041-1049



We have identified 79 mutations in BRCA1 in a set of 643 Dutch and 23 Belgian hereditary breast and ovarian cancer families collected either for research or for clinical diagnostic purposes. Twenty-eight distinct mutations have been observed, 18 of them not previously reported and 12 of them occurring more than once. Most conspicuously, a 2804delAA mutation has been found 19 times and has never been reported outside the Netherlands. A common haplotype spanning > or = 375 kb could be identified for each of the nine examined recurrent mutations, indicating the presence of multiple BRCA1 founder mutations in the Dutch population. The 2804delAA mutation has been estimated to have originated approximately 32 generations ago. No specific breast or ovarian cancer phenotype could be assigned to any of the common mutations, and the ovarian cancer incidence among 18 families with the 2804delAA mutation was heterogeneous.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008041229

Download citation: RISBibTeXText

PMID: 9150151


Related references

Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of Medical Genetics 51(2): 98, 2014

High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Research and Treatment 103(2): 225-232, 2007

A high proportion of founder BRCA1 mutations in Polish breast cancer families. International Journal of Cancer 110(5): 683-686, 2004

Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 53(2): 97, 2006

Prevalence of BRCA1 and BRCA2 founder mutations in Brazilian hereditary breast and ovarian cancer families. Journal of Clinical Oncology 26(15_Suppl): 22108-22108, 2016

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population. Hereditary Cancer in Clinical Practice 16: 12, 2018

Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Human Mutation 22(4): 301-312, 2003

Fifty percent of Jewish high-risk breast and ovarian cancer families are not explained by the three known BRCA1 or BRCA2 founder mutations while a 07 percent combined BRCA1 founder mutation frequency is reported in a Jewish cohort. American Journal of Human Genetics 59(4 Suppl. ): A28, 1996

Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. Journal of Medical Genetics 39(8): 611-614, 2002

A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Casopis Lekaru Ceskych 139(20): 635-637, 2000

A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene. Human Genetics 103(2): 154-161, 1998

BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin. Clinical Genetics 77(1): 60-69, 2010

Large genomic deletions in BRCA1 as major founder mutations among Dutch breast cancer families. American Journal of Human Genetics 61(4 Suppl. ): A14, 1997

BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. International Journal of Cancer 110(5): 677-682, 2004

High prevalence of BRCA1 founder mutations in Greek breast/ovarian families. Clinical Genetics 85(1): 36-42, 2014